In this issue:
First-line dasatinib in chronic-phase CML
Blocking mTOR in AML
Oral As2O3-based maintenance for APL
BCR-ABL1 predicts outcomes in TKI-treated CML
Acute GVHD risk factors after hematopoietic cell transplant
Bexarotene for rare cutaneous T-cell lymphomas
Intensified R-ACVBP vs.standard R-CHOP for DLBCL
R-HyperCVAD active, but toxic, for initial MCL therapy
Rituximab blocks H1N1 vaccine protection
Lymphocytes/monocytes predicts Hodgkin’s lymphoma survival
Please login below to download this issue (PDF)